Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy

Leukemia and Lymphoma

Volumn 47, Issue 9, 2006, Pages 1813-1817

  Lane, Steven W ^a   Crawford, Julie ^b   Kenealy, Melita ^c   Cull, Gavin ^b   Seymour, John F ^c   Prince, H Miles ^c   Marlton, Paula ^a   Gill, Devinder ^a   Mollee, Peter N ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

G CSF; Hyper CVAD; Lymphoid malignancy; Neutropenia; Pegfilgrastim

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CULTURE; BONE MARROW METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INCIDENCE; MALE; MENINGEAL METASTASIS; NEUTROPENIA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THERAPY DELAY; TIME SERIES ANALYSIS; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; SAFETY; TREATMENT OUTCOME; VINCRISTINE;

EID: 33750432899     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600632832     Document Type: Article

References (15)

1. Pettengell, R and Gurney, H and Radford, J and Deakin, D and James, R and Wilkinson, P and (1992) Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial Blood, 80, pp. 1430-1436.
2. Ozer, H and Armitage, J and Bennett, C and Crawford, J and Demetri, G and Pizzo, P and (2000) 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel J Clin Oncol, 18, pp. 3558-3585.
3. Crawford, J. (2003) Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia Semin Oncol, 30, pp. 24-30.
4. Green, M and Koelbl, H and Baselga, J and Galid, A and Guillem, V and Gascon, P and (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy Ann Oncol, 14, pp. 29-35.
5. Holmes, F and O'Shaughnessy, J and Vukelja, S and Jones, S and Shogan, J and Savin, M and (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer J Clin Oncol, 20, pp. 727-731.
6. Vose, J and Crump, M and Lazarus, H and Emmanouilides, C and Schenkein, D and Moore, J and (2003) Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma J Clin Oncol, 21, pp. 514-519.
7. Grigg, A and Solal-Celigny, P and Hoskin, P and Taylor, K and McMillan, A and Forstpointer, R and (2003) Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma Leuk Lymphoma, 44, pp. 1503-1508.
8. Bosi, A and Szer, J and Kassis, J and Sierra, J and Desborough, C and Buchanan, K and (2004) A multicentre, double-blind, randomized, phase 2 trial comparing pegfilgrastim with filgrastim as an adjunct to chemotherapy for acute myeloid leukaemia (AML) Blood, 104, pp. A866. Poster Session
9. Kantarjian, H and O'Brien, S and Smith, T and Cortes, J and Giles, F and Beran, M and (2000) Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia J Clin Oncol, 18, pp. 547-561.
10. Thomas, D and Cortes, J and O'Brien, S and Pierce, S and Faderl, S and Albitar, M and (1999) Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia J Clin Oncol, 17, pp. 2461-2470.
11. Khouri, I and Romaguera, J and Kantarjian, H and Palmer, J and Pugh, W and Korbling, M and (1998) Hyper-CVAD and high-dose methotrexate/ cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma J Clin Oncol, 16, pp. 3803-3809.
12. Molineux, G and Migdalska, A and Haley, J and Evans, G and Dexter, T. (1994) Total marrow failure induced by pegylated stem-cell factor administered before 5-fluorouracil Blood, 83, pp. 3491-3499.
13. Kwak, L and Halpern, J and Olshen, R and Horning, S. (1990) Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis J Clin Oncol, 8, pp. 963-977.
14. Dale, D. (2003) Current management of chemotherapy-induced neutropenia: the role of colony-stimulating factors Semin Oncol, 30, pp. 3-9.
15. E-MIMS. (2005) St Leonards, Havas Medimedia International. Available on CD rom and also online at http://www.mims.com.au